AS
Assembly Biosciences, Inc.
ASMB · NASDAQ
$25.44 +1.60% (+$0.40)
1M -29.22%
Market Cap $494.8M
P/E Ratio -
Div. Yield -
ROE 0.02%
Bulios Fair Price
$13.57
46.7% downside
Current Price
$25.44
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ASMB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
26 /100
Expensive EV/EBITDA 6,836.77x
P/S 6.61x
P/B 1.62x
Growth
100 /100
Growing Book val. growth 35.74%
EPS growth N/A
Rev. growth N/A
Profitability
21 /100
Weak Gross margin 77.73%
Net margin 0.06%
Op. margin 11.76%
Quality
4 /100
Poor ROIC 2.86%
ROE 0.02%
ROA 0.01%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 13.99x
Net debt/EBITDA -440.24x
Stability
57 /100
Moderate Beta 1.13x
EPS volatility 26.96%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ASMB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason A. Okazaki
Employees
73
Headquarters
South San Francisco
Upcoming events
09 NOV
Earnings
Upcoming earnings report